Long non-coding RNAs; potential contributors in cancer chemoresistance through modulating diverse molecular mechanisms and signaling pathways
Pathology - Research and Practice · 2024-08 · 260 · 155455
DOI: 10.1016/j.prp.2024.155455 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2024-08. Verfasst von Hashem O Alsaab und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia. Electronic address: hashemalsaa…. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Drug Resistance, Neoplasm, Neoplasms, Signal Transduction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 192 Literaturangaben. Gefördert von: Deanship of Scientific Research, King Saud University, Shaqra University.
Abstract (Originalsprache)
One of the mainstays of cancer treatment is chemotherapy. Drug resistance, however, continues to be the primary factor behind clinical treatment failure. Gene expression is regulated by long non-coding RNAs (lncRNAs) in several ways, including chromatin remodeling, translation, epigenetic, and transcriptional levels. Cancer hallmarks such as DNA damage, metastasis, immunological evasion, cell stemness, drug resistance, metabolic reprogramming, and angiogenesis are all influenced by LncRNAs. Numerous studies have been conducted on LncRNA-driven mechanisms of resistance to different antineoplastic drugs. Diverse medication kinds elicit diverse resistance mechanisms, and each mechanism may have multiple contributing factors. As a result, several lncRNAs have been identified as new biomarkers and therapeutic targets for identifying and managing cancers. This compels us to thoroughly outline the crucial roles that lncRNAs play in drug resistance. In this regard, this article provides an in-depth analysis of the recently discovered functions of lncRNAs in the pathogenesis and chemoresistance of cancer. As a result, the current research might offer a substantial foundation for future drug resistance-conquering strategies that target lncRNAs in cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics and Pharmaceutical Technology, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia. Electronic address: hashemalsaab@gmail.com.
- Department of Clinical Pharmacy, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
- College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
- Department of Pathological Sciences, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia.
- Department of Pharmacology, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia. Electronic address: Almutairy@su.edu.sa.
Förderung
- Deanship of Scientific Research, King Saud University
- Shaqra University
Zitieren
APA
Alsaab, H. O., Alzahrani, M. S., F Alaqile, A., Waggas, D. S., & Almutairy, B. (2024). Long non-coding RNAs; potential contributors in cancer chemoresistance through modulating diverse molecular mechanisms and signaling pathways. Pathology - Research and Practice, 260, 155455. https://doi.org/10.1016/j.prp.2024.155455
Vancouver
Alsaab HO, Alzahrani MS, F Alaqile A, Waggas DS, Almutairy B. Long non-coding RNAs; potential contributors in cancer chemoresistance through modulating diverse molecular mechanisms and signaling pathways. Pathology - Research and Practice. 2024;260:155455. doi:10.1016/j.prp.2024.155455
BibTeX
@article{Alsaab2024,
author = {Alsaab, Hashem O and Alzahrani, Mohammad S and F Alaqile, Atheer and Waggas, Dania S and Almutairy, Bandar},
title = {Long non-coding RNAs; potential contributors in cancer chemoresistance through modulating diverse molecular mechanisms and signaling pathways},
journal = {Pathology - Research and Practice},
year = {2024},
volume = {260},
pages = {155455},
doi = {10.1016/j.prp.2024.155455}
}
EUVIMED